We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In China, people often equate PV with adverse drug reaction (ADR) monitoring, but in fact, PV is not simply ADR monitoring; it is a gradual outward expanding process with ADR monitoring at its core.
In early September 2018, the National Medical Products Administration of China (NMPA) consecutively released announcements on revision of package inserts of four (varieties of) pharmaceutical products.